The present invention discloses a new use for naringenin as a drug. The new use disclosed in the present invention is the use of naringenin for preparing products for preventing and/or treating abdominal aortic aneurysms. The products comprise drugs and/or health care products. The present invention uses two clinically associated abdominal aortic aneurysm disease models: using angiotensin II (1000 ng/kg/min) through subcutaneous submerging pump to induce ApoE knockout mice and using calcium phosphate (0.5 M) to daub the abdominal aortas of locally induced C57 mice with abdominal aortic aneurysms. Experiments demonstrate that naringenin via oral gavage can significantly inhibit the onset and development of an abdominal aortic aneurysm in the CaPO4 daubed and Angll submerging pump induced mice, and thereby naringenin can be used in the treatment of patients with abdominal aortic aneurysms.
